In early toxicity testing, different techniques such as in vivo and in vitro are used to evaluate the adverse effects of the product on human health. Toxicity tests at early stage of drug development help reduce the risk of later stage failures. As the awareness regarding the welfare of human health and environment has increased, the stringency of regulatory approvals has also increased. As toxicity studies help assess the safety issue of the product, the increased stringency of the government regulators will help increase the adoption rate of toxicity techniques among the different companies. The global early toxicity testing market was $614 million in 2015 and is estimated to reach $1,012 million by 2022, registering a CAGR of 7.3% from 2016 to 2022. Research Beam Model: Research Beam Product ID: 178785 5370 USD New
Early Toxicity Testing Market size and forecast 2014 - 2020
 

Early Toxicity Testing Market by Technique (In vivo, In vitro, and In silico), End Users (Pharmaceuticals Industry, Diagnostics Industry, Food Industry, Chemicals Industry, Cosmetics Industry, and Other Industries) - Global Opportunity Analysis and Industry Forecast, 2014-2022

Early Toxicity Testing Market by Technique (In vivo, In vitro, and In silico), End Users (Pharmaceuticals Industry, Diagnostics Industry, Food Industr

Category : Diagnostic and Biotech
Published On : May  2017
Pages : 220

request-discount


TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

In early toxicity testing, different techniques such as in vivo and in vitro are used to evaluate the adverse effects of the product on human health. Toxicity tests at early stage of drug development help reduce the risk of later stage failures. As the awareness regarding the welfare of human health and environment has increased, the stringency of regulatory approvals has also increased. As toxicity studies help assess the safety issue of the product, the increased stringency of the government regulators will help increase the adoption rate of toxicity techniques among the different companies. The global early toxicity testing market was $614 million in 2015 and is estimated to reach $1,012 million by 2022, registering a CAGR of 7.3% from 2016 to 2022.

Different types of tests such as neurotoxicity, acute toxicity tests, carcinogenicity, and systemic toxicity are conducted using in vivo and in vitro techniques. These tests help to verify if the product is safe for the human health and surrounding environment. Toxicity tests are used for wide variety of products such as cosmetics, food additives, chemicals, pesticides, drugs, and vaccines.

The global early toxicity testing market is attributed to the initiatives taken by the government to spend more on R&D of in vitro and in silico techniques due to the opposition of animal rights organization to use in vivo techniques for toxicity tests. The advancement in in vitro and in silico techniques will positively impact the market growth. However, lack of awareness regarding the benefits of using early toxicity testing among the companies and limitations of preclinical testing are expected to hamper the growth of the global early toxicity testing market.

EARLY TOXICITY TESTING MARKET KEY BENEFITS

  • This report entails detailed quantitative analysis of the current market trends for the period of 2014-2022 to identify the prevailing opportunities.
  • The market estimations provided in the report are based on comprehensive analysis of the key developments in the industry.
  • The global early toxicity testing market is comprehensively analyzed with respect to technique, end users, and geography.
  • In-depth analysis based on geography helps understand the regional market to assist in strategic business planning.
  • The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.

EARLY TOXICITY TESTING MARKET KEY SEGMENTS:

By Technique

  • In Vivo
  • In Vitro
    • By Assay
      • Enzyme Toxicity Assays
      • Bacterial Toxicity Assays
      • Cell-Based ELISA and Western Blots
      • Tissues Culture Assays
      • Receptor Binding Assays
      • Other Assays
    • By Toxicity End-points
      • Dermal Toxicity
      • Systemic Toxicity
      • Carcinogenicity
      • Ocular Toxicity
      • Skin Sensitization and Irritation
      • Genotoxicity
      • Neurotoxicity
      • Organ Toxicity
      • Other Toxicity Endpoints and Tests
  • In silico

By End Users

  • Pharmaceuticals industry
  • Diagnostics industry
  • Food industry
  • Chemicals industry
  • Cosmetics industry
  • Other industries

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Republic of South Africa
    • Rest of LAMEA

The key players profiled in this report include:

  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies Inc.
  • Quest Diagnostics Incorporation
  • Merck & Co., Inc.
  • Charles River Laboratories International Incorporation
  • Becton, Dickinson And Company
  • Danaher Corporation
  • Evotec Ag
  • The Jackson Laboratory

The other players of the early toxicity testing market include (companies not profiled in the report):

  • Covance
  • CellSystems
  • BioQuanta
  • Epithelix
  • Celther Polska
  • HemoGenix

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1.1. CXO perspective

CHAPTER 3 MARKET OVERVIEW

3.1. REPORT DESCRIPTION
3.2. KEY BENEFITS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PATENT ANALYSIS

3.3.1. Patent analysis by year
3.3.2. Patent analysis by region

3.4. GOVERNMENT REGULATIONS
3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Increased stringency of regulatory authorities concerning environment welfare
3.5.1.2. Replacement of in vivo models by in vitro model
3.5.1.3. Increased stringency of regulatory authorities concerning public health welfare
3.5.1.4. Adoption of early toxicity in order to reduce drug failure in later stages

3.5.2. Restrains

3.5.2.1. Limited awareness about the benefits of early toxicity testing
3.5.2.2. Limitation of preclinical testing

3.5.3. Opportunities

3.5.3.1. Advancement in in silico platforms
3.5.3.2. Advancement in in vitro models

CHAPTER 4 GLOBAL EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. IN VIVO

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. IN VITRO

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. In vitro toxicity testing market by assays

4.3.4.1. Enzyme toxicity assays

4.3.4.1.1. Market size and forecast

4.3.4.2. Bacterial toxicity assays

4.3.4.2.1. Market size and forecast

4.3.4.3. Cell-based ELISA and western blots

4.3.4.3.1. Market size and forecast

4.3.4.4. Tissue culture assays

4.3.4.4.1. Market size and forecast

4.3.4.5. Receptor binding assays

4.3.4.5.1. Market size and forecast

4.3.4.6. Other assays

4.3.4.6.1. Market size and forecast

4.3.5. In vitro toxicity testing market by toxicity end-points

4.3.5.1. Dermal toxicity

4.3.5.1.1. Market size and forecast

4.3.5.2. Systemic toxicity

4.3.5.2.1. Market size and forecast

4.3.5.3. Carcinogenicity

4.3.5.3.1. Market size and forecast

4.3.5.4. Ocular toxicity

4.3.5.4.1. Market size and forecast

4.3.5.5. Skin sensitization and irritation

4.3.5.5.1. Market size and forecast

4.3.5.6. Genotoxicity

4.3.5.6.1. Market size and forecast

4.3.5.7. Neurotoxicity

4.3.5.7.1. Market size and forecast

4.3.5.8. Organ toxicity

4.3.5.8.1. Market size and forecast

4.3.5.9. Other toxicity endpoints

4.3.5.9.1. Market size and forecast

4.4. IN SILICO

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

CHAPTER 5 EARLY TOXICITY TESTING MARKET, BY END USERS

5.1. OVERVIEW

5.1.1. Key market trends
5.1.2. Key growth factors and opportunities
5.1.3. Market size and forecast

5.2. PHARMACEUTICAL INDUSTRY

5.2.1. Market size and forecast

5.3. DIAGNOSTICS INDUSTRY

5.3.1. Market size and forecast

5.4. FOOD INDUSTRY

5.4.1. Market size and forecast

5.5. CHEMICALS INDUSTRY

5.5.1. Market size and forecast

5.6. COSMETICS INDUSTRY

5.6.1. Market size and forecast

5.7. OTHER INDUSTRY

5.7.1. Market size and forecast

CHAPTER 6 EARLY TOXICITY TESTING MARKET, BY GEOGRAPHY

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.4. U.S. market size & forecast
6.2.5. Canada market size & forecast
6.2.6. Mexico market size & forecast

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.4. Germany market size & forecast
6.3.5. France market size & forecast
6.3.6. U.K. market size & forecast
6.3.7. Rest of Europe market size & forecast

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.4. Japan market size & forecast
6.4.5. China market size & forecast
6.4.6. Australia market size & forecast
6.4.7. India market size & forecast
6.4.8. Rest of Asia Pacific market size & forecast

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.4. Brazil market size & forecast
6.5.5. Republic of South Africa market size & forecast
6.5.6. Rest of LAMEA market size & forecast

CHAPTER 7 COMPANY PROFILES

7.1. THERMO FISHER SCIENTIFIC INC

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance

7.2. BIO-RAD LABORATORIES, INC.

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance

7.3. AGILENT TECHNOLOGIES INC.

7.3.1. Company overview
7.3.2. Operating business segments
7.3.3. Product portfolio
7.3.4. Business performance

7.4. QUEST DIAGNOSTICS INCORPORATION

7.4.1. Company overview
7.4.2. Operating business segments
7.4.3. Product portfolio
7.4.4. Business performance

7.5. MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN

7.5.1. Company overview
7.5.2. Operating business segments
7.5.3. Product portfolio
7.5.4. Business performance
7.5.5. Key strategic moves & developments, 2014-2016

7.6. CHARLES RIVER LABORATORIES INTERNATIONAL INCORPORATION

7.6.1. Company overview
7.6.2. Operating business segments
7.6.3. Product portfolio
7.6.4. Business performance
7.6.5. Key strategic moves & developments, 2014-2016

7.7. BECTON, DICKINSON AND COMPANY

7.7.1. Company overview
7.7.2. Operating business segments
7.7.3. Product portfolio
7.7.4. Business performance

7.8. DANAHER CORPORATION

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance

7.9. EVOTEC AG

7.9.1. Company overview
7.9.2. Operating business segments
7.9.3. Product portfolio
7.9.4. Business performance
7.9.5. Key strategic moves & developments, 2014-2016

7.10. THE JACKSON LABORATORY

7.10.1. Company overview
7.10.2. Product portfolio
7.10.3. Business performance
7.10.4. Key strategic moves & developments, 2014-2016

LIST OF TABLES

TABLE 1. GLOBAL EARLY TOXICITY TESTING MARKET, BY TECHNIQUE 2014-2022 ($MILLION)
TABLE 2. GLOBAL IN VIVO EARLY TOXICITY TESTING MARKET, BY GEOGRAPHY 2014-2022 ($MILLION)
TABLE 3. GLOBAL IN VITRO EARLY TOXICITY TESTING MARKET, BY GEOGRAPHY 2014-2022 ($MILLION)
TABLE 4. GLOBAL IN VITRO EARLY TOXICITY TESTING MARKET, BY ASSAY 2014-2022 ($MILLION)
TABLE 5. GLOBAL IN VITRO EARLY TOXICITY TESTING MARKET, BY TOXICITY END-POINTS 2014-2022 ($MILLION)
TABLE 6. GLOBAL IN SILICO EARLY TOXICITY TESTING MARKET, BY GEOGRAPHY 2014-2022 ($MILLION)
TABLE 7. GLOBAL EARLY TOXICITY TESTING MARKET, BY END USERS 2014-2022 ($MILLION)
TABLE 8. GLOBAL EARLY TOXICITY TESTING PHARMACEUTICAL INDUSTRY MARKET, BY GEOGRAPHY 2014-2022 ($MILLION)
TABLE 9. GLOBAL EARLY TOXICITY TESTING DIAGNOSTICS INDUSTRY MARKET, BY GEOGRAPHY 2014-2022 ($MILLION)
TABLE 10. GLOBAL EARLY TOXICITY TESTING FOOD INDUSTRY MARKET, BY GEOGRAPHY 2014-2022 ($MILLION)
TABLE 11. GLOBAL EARLY TOXICITY TESTING CHEMICAL INDUSTRY MARKET, BY GEOGRAPHY 2014-2022 ($MILLION)
TABLE 12. GLOBAL EARLY TOXICITY TESTING COSMETICS INDUSTRY MARKET, BY GEOGRAPHY 2014-2022 ($MILLION)
TABLE 13. GLOBAL EARLY TOXICITY TESTING PHARMACEUTICAL INDUSTRY MARKET, BY GEOGRAPHY 2014-2022 ($MILLION)
TABLE 14. GLOBAL EARLY TOXICITY TESTING MARKET, BY GEOGRAPHY 2014-2022 ($MILLION)
TABLE 15. GLOBAL NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE 2014-2022 ($MILLION)
TABLE 16. GLOBAL NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY END USERS 2014-2022 ($MILLION)
TABLE 17. GLOBAL NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY COUNTRY 2014-2022 ($MILLION)
TABLE 18. GLOBAL NORTH AMERICA IN VITRO EARLY TOXICITY TESTING MARKET, BY ASSAY 2014-2022 ($MILLION)
TABLE 19. GLOBAL NORTH AMERICA IN VITRO EARLY TOXICITY TESTING MARKET, BY TOXICITY END-POINTS 2014-2022 ($MILLION)
TABLE 20. GLOBAL EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE 2014-2022 ($MILLION)
TABLE 21. GLOBAL EUROPE EARLY TOXICITY TESTING MARKET, BY END USERS 2014-2022 ($MILLION)
TABLE 22. GLOBAL EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY 2014-2022 ($MILLION)
TABLE 23. GLOBAL EUROPE IN VITRO EARLY TOXICITY TESTING MARKET, BY ASSAY 2014-2022 ($MILLION)
TABLE 24. GLOBAL EUROPE IN VITRO EARLY TOXICITY TESTING MARKET, BY TOXICITY END-POINTS 2014-2022 ($MILLION)
TABLE 25. GLOBAL ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE 2014-2022 ($MILLION)
TABLE 26. GLOBAL ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USERS 2014-2022 ($MILLION)
TABLE 27. GLOBAL ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY COUNTRY 2014-2022 ($MILLION)
TABLE 28. GLOBAL ASIA-PACIFIC IN VITRO EARLY TOXICITY TESTING MARKET, BY ASSAY 2014-2022 ($MILLION)
TABLE 29. GLOBAL ASIA-PACIFIC IN VITRO EARLY TOXICITY TESTING MARKET, BY TOXICITY END-POINTS 2014-2022 ($MILLION)
TABLE 30. GLOBAL LAMEA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE 2014-2022 ($MILLION)
TABLE 31. GLOBAL LAMEA EARLY TOXICITY TESTING MARKET, BY END USERS 2014-2022 ($MILLION)
TABLE 32. GLOBAL LAMEA EARLY TOXICITY TESTING MARKET, BY COUNTRY 2014-2022 ($MILLION)
TABLE 33. GLOBAL LAMEA IN VITRO EARLY TOXICITY TESTING MARKET, BY ASSAY 2014-2022 ($MILLION)
TABLE 34. GLOBAL LAMEA IN VITRO EARLY TOXICITY TESTING MARKET, BY TOXICITY END-POINTS 2014-2022 ($MILLION)
TABLE 35. THERMO FISHER: COMPANY SNAPSHOT
TABLE 36. THERMO FISHER: OPERATING SEGMENTS
TABLE 37. THERMO FISHER: PRODUCT PORTFOLIO
TABLE 38. BIO-RAD: COMPANY SNAPSHOT
TABLE 39. BIO-RAD: OPERATING SEGMENTS
TABLE 40. BIO-RAD: PRODUCT PORTFOLIO
TABLE 41. AGILENT: COMPANY SNAPSHOT
TABLE 42. AGILENT: OPERATING SEGMENTS
TABLE 43. AGILENT: PRODUCT PORTFOLIO
TABLE 44. QUEST DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 45. QUEST DIAGNOSTICS: OPERATING SEGMENTS
TABLE 46. QUEST DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 47. MERCK: COMPANY SNAPSHOT
TABLE 48. MERCK: OPERATING SEGMENTS
TABLE 49. MERCK: PRODUCT PORTFOLIO
TABLE 50. CHARLES RIVER: COMPANY SNAPSHOT
TABLE 51. CHARLES RIVER: OPERATING SEGMENTS
TABLE 52. CHARLES RIVER: PRODUCT PORTFOLIO
TABLE 53. BD: COMPANY SNAPSHOT
TABLE 54. BD: OPERATING SEGMENTS
TABLE 55. BD: PRODUCT PORTFOLIO
TABLE 56. DANAHER: COMPANY SNAPSHOT
TABLE 57. DANAHER: OPERATING SEGMENTS
TABLE 58. DANAHER: PRODUCT PORTFOLIO
TABLE 59. EVOTEC: COMPANY SNAPSHOT
TABLE 60. EVOTEC: OPERATING SEGMENTS
TABLE 61. EVOTEC: PRODUCT PORTFOLIO
TABLE 62. JAX: COMPANY SNAPSHOT
TABLE 63. JAX: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. GLOBAL EARLY TOXICITY TESTING MARKET: SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS: GLOBAL EARLY TOXICITY TESTING MARKET, BY END USERS
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
FIGURE 4. PATENT REGISTERED/APPROVED- BY YEAR
FIGURE 5. PATENT REGISTERED/APPROVED- BY REGION
FIGURE 6. ENZYME TOXICITY ASSAYS FOR EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 7. BACTERIAL TOXICITY ASSAYS FOR EARLY TOXICITY TESTING MARKET, 2014-2022($MILLION)
FIGURE 8. CELL-BASED ELISA AND WESTERN BLOTS FOR EARLY TOXICITY TESTING MARKET, 2014-2022($MILLION)
FIGURE 9. TISSUE CULTURE ASSAYS FOR EARLY TOXICITY TESTING MARKET, 2014-2022($MILLION)
FIGURE 10. RECEPTOR BINDING ASSAYS FOR EARLY TOXICITY TESTING MARKET, 2014-2022($MILLION)
FIGURE 11. OTHER IN VITRO ASSAYS FOR EARLY TOXICITY TESTING MARKET, 2014-2022($MILLION)
FIGURE 12. DERMAL TOXICITY FOR EARLY TOXICITY TESTING MARKET, 2014-2022
FIGURE 13. SYSTEMIC TOXICITY TESTS FOR EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 14. CARCINOGENICITY FOR EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 15. OCULAR TOXICITY FOR EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 16. SKIN SENSITIZATION AND IRRITATION FOR EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 17. GENOTOXICITY FOR EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 18. NEUROTOXICITY FOR EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 19. ORGAN TOXICITY FOR EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 20. OTHER TOXICITY ENDPOINTS FOR EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 21. U.S. EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 22. CANADA EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 23. MEXICO EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 24. GERMANY EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 25. FRANCE EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 26. U.K. EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 27. REST OF EUROPE EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 28. JAPAN EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 29. CHINA EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 30. AUSTRALIA EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 31. INDIA EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 32. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 33. BRAZIL EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 34. REPUBLIC OF SOUTH AFRICA EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 35. REST OF LAMEA EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 36. THERMO FISHER: REVENUE, 2014-2016 ($MILLION)
FIGURE 37. THERMO FISHER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 38. THERMO FISHER: REVENUE SHARE, BY GEOGRAPHY, 2016 (%)
FIGURE 39. BIO-RAD: REVENUE, 2014-2016 ($MILLION)
FIGURE 40. BIO-RAD: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 41. BIO-RAD: REVENUE SHARE, BY GEOGRAPHY, 2016 (%)
FIGURE 42. AGILENT: REVENUE, 2014-2016
FIGURE 43. AGILENT: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 44. AGILENT: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 45. QUEST: REVENUE, 2014-2016 ($MILLION)
FIGURE 46. AGILENT: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 47. MERCK: REVENUE, 2014-2016 ($MILLION)
FIGURE 48. MERCK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 49. MERCK: REVENUE SHARE, BY GEOGRAPHY, 2016 (%)
FIGURE 50. MERCK: STRATEGY SHARE, 2014-2016 (%)
FIGURE 51. CHARLES RIVER: REVENUE, 2014-2016 ($MILLION)
FIGURE 52. CHARLES RIVER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 53. CHARLES RIVER: REVENUE SHARE, BY GEOGRAPHY, 2016 (%)
FIGURE 54. CHARLES RIVER: STRATEGY SHARE, 2014-2016 (%)
FIGURE 55. BD: REVENUE, 2014-2016 ($MILLION)
FIGURE 56. BD: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 57. BD: REVENUE SHARE, BY GEOGRAPHY, 2016 (%)
FIGURE 58. DANAHER: REVENUE, 2014-2016 ($MILLION)
FIGURE 59. DANAHER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 60. DANAHER: REVENUE SHARE, BY GEOGRAPHY, 2016 (%)
FIGURE 61. EVOTEC: REVENUE, 2013-2015 ($MILLION)
FIGURE 62. EVOTEC: REVENUE SHARE BY SEGMENT, 2015 (%)
FIGURE 63. EVOTEC: REVENUE SHARE, BY GEOGRAPHY, 2015 (%)
FIGURE 64. EVOTEC: STRATEGY SHARE, 2014-2016 (%)
FIGURE 65. JAX: REVENUE, 2013-2015 ($MILLION)
FIGURE 66. JAX: STRATEGY SHARE, 2014-2016 (%)

Enquiry Before Buy